Our Pipeline
At Remi Therapeutics, our developmental approach is focused on leveraging trusted science and proven biological pathways to identify and develop agents that are more precise, safer, and offer an improved risk-benefit profile compared to existing therapies. This strategy enables us to rapidly and cost-effectively commercialize treatments that build on established data and science, ultimately providing better solutions for patients and a rapid return for our investors.
Assets & Pathways
Proposed Mechanism of Action
RT0306 is a novel therapeutic agent designed to modulate neurotransmitters and neuroinflammation offering a potential multi-faceted approach to the treatment of Autism Spectrum Disorder (ASD).
The multi-faceted targeting approach of RT0306 not only addresses core symptoms of Autism Spectrum Disorder but also helps to minimize common side effects, thereby improving patient adherence and overall treatment outcomes. This makes RT0306 a promising candidate for first-line therapy in ASD or as an adjunctive treatment to enhance the efficacy of existing therapies.